Alembic Pharma Metolazone Tablets get USFDA nod
Metolazone Tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
Vadodara: Pharma major, Alembic Pharmaceuticals Limited, has recently announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Metolazone Tablets USP 2.5 mg, 5 mg, and 10 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Zaroxolyn Tablets 2.5 mg, 5 mg, and 10 mg, of Lannett Company, Inc.
Metolazone Tablets are indicated for the treatment of salt and water retention including:
a) edema accompanying congestive heart failure;
b) edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
Metolazone Tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
Metolazone Tablets USP 2.5 mg, 5 mg, and 10 mg have an estimated market size of US$ 33 million for twelve months ending September 2020 according to IQVIA. Alembic has a cumulative total of 137 ANDA approvals (118 final approvals and 19 tentative approvals) from USFDA.
Read also: Alembic Pharma associate firm gets USFDA nod for trial on retroviral oral drug for COVID treatment
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.